Lexeo Therapeutics (LXEO) Depreciation & Amortization (CF) (2022 - 2026)
Lexeo Therapeutics recorded quarterly Depreciation & Amortization (CF) of $73000.0 in Q1 2026, little changed quarter-over-quarter from $73000.0 in Q4 2025, and up 21.67% year-over-year from $60000.0 in Q1 2025.
Lexeo Therapeutics' Depreciation & Amortization (CF) history runs 5 years deep, the most recent figure standing at $73000.0 for Q1 2026.
- In Q1 2026, Depreciation & Amortization (CF) rose 21.67% year-over-year to $73000.0; the TTM figure through Mar 2026 stood at $281000.0 (down 4.75% YoY), while the FY2025 annual figure was $268000.0, down 11.84% from the prior year.
- Depreciation & Amortization (CF) came in at $73000.0 for Q1 2026 at Lexeo Therapeutics, roughly flat from $73000.0 in the prior quarter.
- In the past five years, Depreciation & Amortization (CF) ranged from a high of $83000.0 in Q3 2024 to a low of $57000.0 in Q1 2023.
- A 5-year average of $69571.4 and a median of $73000.0 in 2025 frame the typical range for Depreciation & Amortization (CF).
- Across the five-year window, Depreciation & Amortization (CF) jumped 32.76% in 2023 and slipped 19.48% in 2025, its largest moves.
- Lexeo Therapeutics' Depreciation & Amortization (CF) stood at $58000.0 in 2022, then jumped by 32.76% to $77000.0 in 2023, then decreased by 2.6% to $75000.0 in 2024, then declined by 2.67% to $73000.0 in 2025, then changed by 0.0% to $73000.0 in 2026.
- According to Business Quant data, Depreciation & Amortization (CF) over the past three periods registered $73000.0, $73000.0, and $73000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Depreciation & Amortization (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | 1,395.22 |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | - |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 55.90 Mn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 123.20 Mn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 13.55 Mn |
| 10 | Lexeo Therapeutics | 392.12 Mn | 199.07 Mn | - | 73,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 73,000.00 |
| Mar 31, 2026 | 73,000.00 |
| Dec 31, 2025 | 73,000.00 |
| Dec 31, 2025 | 73,000.00 |
| Sep 30, 2025 | 73,000.00 |
| Sep 30, 2025 | 73,000.00 |
| Jun 30, 2025 | 62,000.00 |
| Jun 30, 2025 | 62,000.00 |
| Mar 31, 2025 | 60,000.00 |
| Mar 31, 2025 | 60,000.00 |
| Dec 31, 2024 | 75,000.00 |
| Dec 31, 2024 | 75,000.00 |
| Sep 30, 2024 | 83,000.00 |
| Sep 30, 2024 | 83,000.00 |
| Jun 30, 2024 | 77,000.00 |
| Jun 30, 2024 | 77,000.00 |
| Mar 31, 2024 | 69,000.00 |
| Mar 31, 2024 | 69,000.00 |
| Dec 31, 2023 | 77,000.00 |
| Dec 31, 2023 | 77,000.00 |
| Sep 30, 2023 | 78,000.00 |
| Sep 30, 2023 | 78,000.00 |
| Jun 30, 2023 | 59,000.00 |
| Jun 30, 2023 | 59,000.00 |
| Mar 31, 2023 | 57,000.00 |
| Mar 31, 2023 | 57,000.00 |
| Dec 31, 2022 | 58,000.00 |
| Dec 31, 2022 | 58,000.00 |